4,000,000 Shares of Common Stock BIOXCEL THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 31st, 2020 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell 4,000,000 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, certain stockholders of the Company named in Schedule II attached hereto (each, a “Selling Stockholder” and collectively, the “Selling Stockholders”), acting severally and not jointly, propose to grant to the underwriters named in Schedule I (the “Underwriters”) attached to this agreement (this “Agreement”) an option to purchase up to an aggregate of 600,000 additional shares of the Common Stock on the terms set forth in Section 3 (the “Option Stock”), with the maximum number of shares of Option Shares being sold by each Selling Stockholder set forth in Schedule II hereto. The Firm Stock and the Option Stock, if purchased, are hereinafter collectively called the “Stock”. This Agreement is to confirm the agreement concerning the purchase of the Stock from the Company and the S
